Side-by-side · Research reference
PT-141vsVilon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED13/41 cited
BAnimal-StrongHUMAN-REVIEWED13/49 cited
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
Vilon
Khavinson Bioregulator · Dipeptide
Literature lacks standardised clinical route
01Mechanism of Action
Parameter
PT-141
Vilon
Primary target
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Immune cell differentiation pathways, chromatin modification
Pathway
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)
Downstream effect
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011Khavinson 2002Lezhava 2023
Feedback intact?
—
Unknown — no HPA/HPG axis data
Origin
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997
Antibody development
—
—
02Dosage Protocols
Parameter
PT-141
Vilon
Standard dose
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
No clinical standard — literature lacks human dosing
Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Frequency
PRN, max 8 doses / month
Unknown — literature does not specify chronic administration protocols
Lower / starter dose
1 mg (off-label)
—
Evidence basis
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Mouse / in vitro only
Duration
PRN; reassess if no benefit after 8 doses
Not characterised in humans
Reconstitution
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
—
Timing
≥45 min before sexual activity
—
Half-life
Not published — dipeptides typically <10 min plasma t½
Animal model dose
—
In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)
Not translatable to human mg/kg without pharmacokinetic data.
Route
—
Likely SQ or oral (Khavinson school uses both); no published ROA validation
04Side Effects & Safety
Parameter
PT-141
Vilon
Flushing
Common, transient
—
Injection site reaction
Erythema, mild pain
—
Headache
Common
—
Hyperpigmentation (focal)
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
—
Hypertension (transient)
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
—
Pregnancy / OB
Contraindicated
—
Cardiovascular disease
Use caution; transient BP rise
—
Human safety data
—
Absent from PubMed-indexed literature
Theoretical risk
—
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Antibody formation
—
Not reported; dipeptides generally low immunogenicity
Animal models
—
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute Contraindications
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Vilon
- ·Active autoimmune disease (theoretical — no clinical data)
Relative Contraindications
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
Vilon
- ·Pregnancy / lactation (no safety data)
- ·Acute infection with cytokine storm risk (immune modulation unknown)
05Administration Protocol
Parameter
PT-141
Vilon
1. Reconstitution
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.
2. Injection site
SQ — abdomen or thigh.
Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.
3. Timing
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.
4. Storage
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
Likely lyophilised powder, refrigerated. Reconstitution protocols not published.
5. Needle
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
—
06Stack Synergy
PT-141
— no documented stacks
Vilon
+ Epitalon
ModerateBoth are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.
- Vilon
- Empirical — no standard
- Epitalon
- Empirical — often 10 mg cycles
- Frequency
- Sequential or concurrent (literature ambiguous)
- Primary benefit
- Multi-system aging modulation (immune + pineal/circadian)
+ Thymalin
WeakThymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.
- Vilon
- No standard
- Thymalin
- 10–100 mg IM (polypeptide complex)
- Primary benefit
- Redundant — both target T-cell differentiation